Yuhan patents preclinical LOX inhibitor targeting four fibrotic diseases
AI Summary- Yuhan patented an undisclosed LOX-inhibiting candidate for multi-organ fibrosis.
- The U.S. patent covers IPF, MASH, CKD and liver cirrhosis.
- YH25724 entered domestic Phase 1 planning after approval in May this year.